27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
LATE-NC is a common TDP-43 proteinopathy, associated with an amnestic dementia syndrome that mimicked Alzheimer's-type dementia in retrospective autopsy studies. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our results suggest that higher glucose levels may be a risk factor for dementia, even among persons without diabetes. 4 key findings →
Participants: 839 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
As there is currently no cure for dementia, there is an urgent need for preventive strategies. 5 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Diabetes prevention and glucose control in midlife may protect against late-life cognitive decline. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A systematic review was conducted to identify risk factors associated with the onset and progression of Alzheimer's disease (AD). 5 key findings →
Design: systematic review Participants: 65 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A combination of modifiable vascular risk factors in midlife is highly predictive of the likelihood of dementia decades later. 1 key finding →
Design: cohort study Participants: 2,767 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Atrial fibrillation, hypertension, and angina were associated with a greater rate of decline and may represent modifiable risk factors for secondary prevention in Alzheimer disease. 3 key findings →
Design: longitudinal study Participants: 135 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Evidence that short-term, single-component physical activity interventions promote cognitive function and prevent cognitive decline or dementia in older adults is largely insufficient. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our results suggest that having an increased body weight or abdominal obesity are associated with increased dementia incidence. 5 key findings →
Design: longitudinal study Participants: 453 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In older adults with normal cognition, training improves cognitive performance in the domain trained. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cox regression and accelerated failure time models were used to investigate whether sex, apolipoprotein E genotype and e4 carriage were associated with amyloid onset age in all cohorts. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Main results Four trials including 15,936 hypertensive subjects were identified. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our findings provide robust evidence supporting the protective effect of the Mediterranean diet against stroke. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment and intervention thresholds, management of vertebral fractures, non-pharmacological and pharmacological treatments, including duration and monitoring of anti-resorptive therapy, glucocorticoid-induced osteoporosis, as well as models of care for fracture prevention. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 172 patients were included (86 each in the sotatercept and placebo groups). 5 key findings →
Design: clinical trial Participants: 172 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A reduction in the incidence of smoking will likely reduce the future prevalence of AD. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
To examine the relationship between smoking and Alzheimer's disease (AD) after controlling for study design, quality, secular trend, and tobacco industry affiliation of the authors, electronic databases were searched; 43 individual studies met the inclusion criteria. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
This expert commission synthesized decades of population-level (observational) research to estimate how much dementia risk could theoretically be reduced by addressing 14 modifiable risk factors across life, from childhood education to late-life social isolation. 3 key findings →
Design: systematic-review Evidence: moderate
Full summary, score breakdown and related studies → Original source
Using nearly 8,000 British civil servants followed for up to 25 years (the Whitehall II study), this study found that people who slept 6 hours or less per night in their 50s and 60s had a higher later risk of dementia than those sleeping about 7 hours, even after accounting for other health and social factors. 4 key findings →
Design: cohort Participants: 7,959 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This unusually long 28-year study found no evidence that being physically active in midlife protects against dementia later in life. 4 key findings →
Design: cohort Participants: 10,308 Evidence: null result
Full summary, score breakdown and related studies → Original source
This 28-year study tracked depressive symptoms in over 10,000 people and found that depression appearing later in life (closer to a dementia diagnosis) was linked to higher dementia risk, but depression in midlife (decades before diagnosis) was not. 4 key findings →
Design: cohort Participants: 10,189 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among eligible participants (n = 705,061), 264,294 individuals (37.5% of eligible participants) initiated any statin during 2001-2010 ("initiators"), of whom 249,613 (94.4%) were matched with 255,937 unique noninitiators to create the analytic sample (322,358 unique participants; mean age at baseline = 67.4 years; 55.1% female). 3 key findings →
Design: cohort Participants: 322,358 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
No significant association was found between MHT use and risk of mild cognitive impairment or dementia. 2 key findings →
Design: meta-analysis Participants: 1,016,055 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our findings showed significant associations between hearing and vision impairments and increased risks of all-cause and cause-specific dementia. 5 key findings →
Design: meta-analysis Participants: 937,908 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →